SCHEDULE: T. Rowe Price Adjusts Kenvue Stake to 1.0%

T. Rowe Price Associates, Inc. reported a 1.0% beneficial ownership stake in Kenvue Inc. common stock as of December 31, 2025.

Summary

• T. Rowe Price Associates, Inc. filed an Amendment No. 6 to Schedule 13G regarding its beneficial ownership in Kenvue Inc.
• As of December 31, 2025, T. Rowe Price beneficially owned an aggregate of 19,752,028 shares of Kenvue Inc. common stock.
• This represents 1.0% of Kenvue Inc.'s outstanding common stock.
• T. Rowe Price holds sole voting power over 19,227,798 shares and sole dispositive power over 19,751,964 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive disclosure. While the 1.0% stake is not substantial, the continued presence of a major institutional investor like T. Rowe Price in Kenvue's shareholder base provides a baseline level of institutional confidence.

Positives

• The filing itself does not contain specific positive financial or operational news for Kenvue Inc. It is a disclosure of an institutional investment position.

Negatives

• The filing itself does not contain specific negative financial or operational news for Kenvue Inc. It is a disclosure of an institutional investment position.

Risks

• NA

Future Outlook

NA

Management Comments

• T. Rowe Price Associates, Inc. certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Kenvue Inc.
• T. Rowe Price Associates, Inc. expressly denies beneficial ownership of the securities referred to, stating that the filing of Schedule 13G shall not be construed as an admission of such.

Industry Context

StockSavvy.ai notes that T. Rowe Price Associates, Inc. is a prominent global asset manager. Their continued disclosure of a stake in Kenvue, even at 1.0%, indicates ongoing institutional interest in the consumer health sector. While a 1% stake is not a controlling interest, it reflects a position within a diversified portfolio managed by a significant investment adviser.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure for institutional investors under SEC Rule 13d-1(b).
• It does not provide performance metrics for Kenvue Inc. that would allow for direct comparison to industry peers like Procter & Gamble (PG), Johnson & Johnson (JNJ), or Unilever (UL) in terms of operational results.
• Instead, it details an investment position, which is a common practice for large asset managers like BlackRock, Vanguard, or Fidelity, who routinely disclose their holdings in public companies.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
• Management: Awareness of institutional ownership can influence strategic decisions and communication with the investment community.

Key Dates

Recommendation

The filing is a routine disclosure of institutional ownership and does not contain new information about Kenvue's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. T. Rowe Price's 1.0% stake is a standard institutional holding, suggesting a 'hold' stance as there are no new catalysts or red flags presented by this specific filing.

Keywords

Kenvue Inc., KVUE, T. Rowe Price Associates, Investment Adviser, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor